Elevance Health, Inc. $ELV Stock Purchased by State Street Corp

Elevance Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street increased its Elevance Health stake by 0.6% in the third quarter, adding 67,221 shares to hold about 10.49 million shares valued at $4.08 billion. Institutional investors own 89.24% of the company.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $458.91; 16 analysts rate the stock Buy and seven rate it Hold.
  • Elevance reported quarterly earnings of $6.99 per share, exceeding the $4.71 consensus estimate, and declared a quarterly dividend of $1.72 per share.
  • Interested in Elevance Health? Here are five stocks we like better.

State Street Corp boosted its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 0.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,493,831 shares of the company's stock after purchasing an additional 67,221 shares during the period. State Street Corp owned approximately 4.86% of Elevance Health worth $4,080,211,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Elevance Health in the second quarter valued at about $7,344,424,000. Wellington Management Group LLP boosted its stake in Elevance Health by 12.0% during the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company's stock valued at $3,563,142,000 after acquiring an additional 984,976 shares during the last quarter. First Eagle Investment Management LLC lifted its position in shares of Elevance Health by 1.4% during the second quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company's stock worth $1,619,701,000 after purchasing an additional 55,905 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Elevance Health in the 2nd quarter worth approximately $1,246,349,000. Finally, Bank of America Corp DE boosted its holdings in Elevance Health by 23.2% in the first quarter. Bank of America Corp DE now owns 2,718,766 shares of the company's stock worth $795,919,000 after purchasing an additional 511,626 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Morgan Stanley increased their price target on Elevance Health from $404.00 to $449.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 22nd. Royal Bank Of Canada increased their price objective on shares of Elevance Health from $424.00 to $455.00 and gave the company a "sector perform" rating in a report on Thursday, October 22nd. Guggenheim lifted their target price on Elevance Health from $460.00 to $485.00 and gave the stock a "buy" rating in a report on Thursday, October 22nd. Robert W. Baird upped their price target on Elevance Health from $393.00 to $406.00 and gave the company a "neutral" rating in a report on Thursday, October 22nd. Finally, UBS Group boosted their price objective on Elevance Health from $460.00 to $523.00 and gave the stock a "buy" rating in a report on Thursday, October 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $458.91.

Get Our Latest Report on Elevance Health

Insider Activity at Elevance Health

In other Elevance Health news, Director Ramiro Peru acquired 1,000 shares of the business's stock in a transaction that occurred on Thursday, November 19th. The shares were purchased at an average price of $383.86 per share, with a total value of $383,860.00. Following the completion of the transaction, the director owned 11,908 shares in the company, valued at $4,571,004.88. The trade was a 9.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the sale, the executive vice president owned 14,849 shares of the company's stock, valued at $6,533,560. This trade represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.34% of the company's stock.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $394.40 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The business's 50-day moving average price is $415.92 and its two-hundred day moving average price is $376.97. The company has a market capitalization of $85.21 billion, a P/E ratio of 16.82, a price-to-earnings-growth ratio of 1.82 and a beta of 0.63.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, topping analysts' consensus estimates of $4.71 by $2.28. The company had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business's quarterly revenue was up .7% on a year-over-year basis. During the same period last year, the business earned $6.03 EPS. Analysts anticipate that Elevance Health, Inc. will post 29.16 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health's dividend payout ratio (DPR) is presently 29.34%.

Elevance Health Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Featured Articles

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Elevance Health Right Now?

Before you consider Elevance Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.

While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines